secwatch.observer — SEC 8-K summary
======================================

Issuer:     CHEMED CORP (CHE)
CIK:        0000019584
Form:       8-K
Filed at:   2022-04-26T23:59:59+00:00
Accession:  0001562762-22-000191
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Chemed Q1 2022: EPS up 7.9% on adjusted basis; VITAS revenue down 5.3%, Roto-Rooter up 9.4%
--------------------------------------------------------------------------------

- Consolidated revenue $531M (+0.6% YoY); GAAP diluted EPS $4.22 (+5.2%); adjusted diluted EPS $4.79 (+7.9%).
- VITAS net patient revenue $299M (-5.3%), ADC 17,313 (-4.1%), admissions 16,530 (-8.9%).
- Roto-Rooter revenue $231M (+9.4%); net income excl. discrete items $46.4M (+18.0%); adjusted EBITDA margin 28.5% (+160 bps).
- Chemed repurchased 57,500 shares for $27.4M at avg. cost $475.71; remaining auth. ~$175M.
- Management to provide updated 2022 earnings guidance in June 2022 earnings release.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/19584/000156276222000191/0001562762-22-000191-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/19584/000156276222000191/che-20220426x8k.htm
  HTML page:      https://secwatch.observer/filing/0001562762-22-000191

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer